ORGANON & CO. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.55 USD | +0.71% |
|
+4.10% | +28.64% |
| Apr. 09 | Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating | MT |
| Apr. 08 | Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,721 | 7,104 | 3,686 | 4,771 | - | - |
| Enterprise Value (EV) 1 | 16,118 | 15,311 | 11,753 | 12,267 | 11,598 | 10,866 |
| P/E ratio | 5.73 x | 7.78 x | 3.61 x | 6.1 x | 4.89 x | 4.44 x |
| Yield | 1.84% | 4.01% | 7.77% | 5.97% | 6.2% | 6.04% |
| Capitalization / Revenue | 1.22 x | 1.15 x | 0.59 x | 0.75 x | 0.74 x | 0.73 x |
| EV / Revenue | 2.56 x | 2.48 x | 1.88 x | 1.92 x | 1.8 x | 1.67 x |
| EV / EBITDA | 6.77 x | 7.34 x | 6.05 x | 6.14 x | 5.6 x | 5.12 x |
| EV / FCF | 8.19 x | 23.1 x | 21.4 x | 14.5 x | 11.1 x | 9.8 x |
| FCF Yield | 12.2% | 4.32% | 4.66% | 6.91% | 8.99% | 10.2% |
| Price to Book | - | -7.99 x | -52.7 x | 8.83 x | 3.57 x | 2.13 x |
| Nbr of stocks (in thousands) | 253,550 | 254,364 | 255,606 | 257,173 | - | - |
| Reference price 2 | 30.45 | 27.93 | 14.42 | 18.55 | 18.55 | 18.55 |
| Announcement Date | 2/17/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,096 | 6,304 | 6,174 | 6,263 | 6,373 | 6,458 | 6,515 |
| EBITDA 1 | - | 2,379 | 2,085 | 1,944 | 1,998 | 2,073 | 2,121 |
| EBIT 1 | - | 2,184 | 1,873 | 1,874 | 1,868 | 1,942 | 1,977 |
| Operating Margin | - | 34.64% | 30.34% | 29.92% | 29.32% | 30.07% | 30.34% |
| Earnings before Tax (EBT) | - | 1,529 | 1,122 | 673 | - | - | - |
| Net income 1 | 2,160 | 1,351 | 917 | 1,023 | 788 | 981 | 1,082 |
| Net margin | 26.68% | 21.43% | 14.85% | 16.33% | 12.36% | 15.19% | 16.61% |
| EPS 2 | - | 5.310 | 3.590 | 3.990 | 3.040 | 3.790 | 4.180 |
| Free Cash Flow 1 | - | 1,968 | 662 | 548 | 847.3 | 1,042 | 1,109 |
| FCF margin | - | 31.22% | 10.72% | 8.75% | 13.3% | 16.14% | 17.02% |
| FCF Conversion (EBITDA) | - | 82.72% | 31.75% | 28.19% | 42.41% | 50.29% | 52.26% |
| FCF Conversion (Net income) | - | 145.67% | 72.19% | 53.57% | 107.53% | 106.25% | 102.46% |
| Dividend per Share 2 | - | 0.5600 | 1.120 | 1.120 | 1.108 | 1.150 | 1.120 |
| Announcement Date | 4/14/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,600 | 1,604 | 1,567 | 1,585 | 1,537 | 1,485 | 1,538 | 1,608 | 1,519 | 1,598 | 1,561 | 1,629 | 1,564 | 1,607 | 1,560 |
| EBITDA 1 | 636 | 549 | 647 | 512 | 546 | 380 | 518 | 530 | 447 | 449 | 451 | 515 | 515 | 527 | - |
| EBIT 1 | 584 | 487 | 594 | 462 | 489 | 328 | 461 | 472 | 430 | 436 | 437.6 | 479.4 | 482.1 | 498 | - |
| Operating Margin | 36.5% | 30.36% | 37.91% | 29.15% | 31.82% | 22.09% | 29.97% | 29.35% | 28.31% | 27.28% | 28.03% | 29.43% | 30.83% | 30.99% | - |
| Earnings before Tax (EBT) | 389 | 236 | - | 287 | 282 | 111 | 235 | 254 | 80 | 104 | - | - | - | - | - |
| Net income | 323 | 202 | - | 234 | 227 | 108 | 177 | 242 | 58 | 546 | - | - | - | - | - |
| Net margin | 20.19% | 12.59% | - | 14.76% | 14.77% | 7.27% | 11.51% | 15.05% | 3.82% | 34.17% | - | - | - | - | - |
| EPS | 1.270 | 0.7900 | 1.360 | 0.9200 | 0.8900 | 0.4200 | 0.6900 | 0.9500 | 0.2300 | 2.130 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | 0.2800 | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 2/17/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/16/23 | 5/4/23 | 8/8/23 | 11/2/23 | 2/15/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 8,397 | 8,207 | 8,067 | 7,497 | 6,827 | 6,095 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 3.53 x | 3.936 x | 4.15 x | 3.752 x | 3.294 x | 2.873 x |
| Free Cash Flow 1 | - | 1,968 | 662 | 548 | 847 | 1,042 | 1,109 |
| ROE (net income / shareholders' equity) | - | 67.9% | - | - | 283% | 201% | 80.1% |
| ROA (Net income/ Total Assets) | - | 13% | 11.9% | 9.22% | 9.83% | 9.9% | 9.69% |
| Assets 1 | - | 10,395 | 7,726 | 11,094 | 8,013 | 9,910 | 11,163 |
| Book Value Per Share 2 | - | - | -3.500 | -0.2700 | 2.100 | 5.200 | 8.700 |
| Cash Flow per Share 2 | - | 8.500 | 3.360 | 3.120 | 4.460 | 5.070 | - |
| Capex 1 | - | 192 | 196 | 51 | 228 | 227 | 229 |
| Capex / Sales | - | 3.05% | 3.17% | 0.81% | 3.58% | 3.51% | 3.52% |
| Announcement Date | 4/14/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
18.55
USD
Average target price
21.5
USD
Spread / Average Target
+15.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.64% | 4.77B | |
| +25.83% | 661B | |
| +26.16% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.58% | 231B | |
| +5.34% | 200B | |
| -9.00% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- OGN Stock
- Financials Organon & Co.
